Sana Biotechnology presented its Type 1 diabetes program, SC451, at Citigroup's Biopharma Back to School Summit on September 10, 2026. SC451 is a gene‑modified, stem‑cell‑derived islet therapy intended to achieve a functional cure with a single injection and no lifelong immunosuppression.
The company indicated that an investigational new drug (IND) filing for SC451 is imminent and that the first patient dose could be administered shortly after regulatory clearance. Proof‑of‑concept data are expected about one month after the initial dose, with additional efficacy and consistency results projected throughout 2027.
Sana reported a cash balance of $160 million at the end of the latest quarter, sufficient to fund approximately one year of operations. The firm posted a current ratio of 1.38, a debt‑to‑equity ratio of 0.52, and a last‑twelve‑month EBITDA loss of $174 million, translating to a loss per share of $0.76. The stock traded at $3.04, down 4.1% from $3.17, with a 52‑week range of $2.61 to $6.55, a weekly decline of 19%, and a beta of 2.13. Analyst price targets range between $6 and $12.
Globally, about 10 million people live with Type 1 diabetes, with roughly 500,000 new diagnoses each year. In the United States, the patient pool is estimated at 1.5‑2 million, with 70,000‑80,000 new cases annually. Current care leaves patients with a life expectancy 7‑10 years shorter than the general population, a reduction comparable to HIV or breast cancer diagnoses.
CEO Steve emphasized the goal of a functional cure, stating, "Our goal is very simple. It's a functional cure. It is one injection of cells that will lead to normal blood sugars or euglycemia, with no immunosuppression for life for these patients." He added that the company is "getting very close" to starting the SC451 trial and acknowledged future manufacturing capacity constraints, noting that meeting the unmet need could keep the firm capacity‑constrained for years.
Sana also discussed its in‑vivo CAR‑T program, SG293, which targets CD19 using fusogen technology. Regulatory delays in China have pushed the first data release to the first half of 2027. Steve described the setback as disappointing but not fatal, remarking that "things that we would kind of, I might call rubber stamps have become signatures."
